Results 261 to 270 of about 25,762 (279)
Some of the next articles are maybe not open access.
Proteinuria and Exposure to Eculizumab in Atypical Hemolytic Uremic Syndrome
American Society of Nephrology. Clinical Journal, 2023Visual Abstract Background Eculizumab is a monoclonal antibody for the treatment of atypical hemolytic uremic syndrome (aHUS). Kidney damage, a common condition in patients with aHUS, may result in proteinuria.
Mendy ter Avest +9 more
semanticscholar +1 more source
Atypical hemolytic uremic syndrome
Current Opinion in Hematology, 2010The last few years revealed a molecular distinction between thrombotic thrombocytopenic purpura, a disease characterized by a lack of ADAMTS13 activity, and atypical hemolytic uremic syndrome (aHUS), a disease of complement overactivation. Many different predisposing genetic factors resulting in complement overactivation have been described in aHUS ...
Kavanagh D, Goodship THJ
openaire +3 more sources
Atypical hemolytic uremic syndrome
Pediatrics International, 1995AbstractThe pathogenesis of atypical uremic syndrome (HUS), which is rarely encountered in childhood, is poorly understood and its mortality and morbidity rates are high. A wide variety of therapeutic approaches has been attempted and the literature contains numerous conflicting reports about the results of these approaches.
İRKEN G. +3 more
openaire +3 more sources
Atypical Hemolytic–Uremic Syndrome
New England Journal of Medicine, 2009The hemolytic–uremic syndrome, which is characterized by nonimmune hemolytic anemia, thrombocytopenia, and renal impairment, occurs most frequently in young children. Most cases are secondary to infection with Escherichia coli O157:H7 and other Shiga-toxin–producing strains.
Marina, Noris, Giuseppe, Remuzzi
openaire +2 more sources
Plasmatherapy in Atypical Hemolytic Uremic Syndrome
Seminars in Thrombosis and Hemostasis, 2010Plasmatherapy has become empirically first-line treatment in atypical hemolytic uremic syndrome (aHUS), although no prospective controlled trials have been conducted. Patients with mutations that induce complete or partial factor H (FH) quantitative deficiency may be controlled by plasma infusions (PI), but plasma exchanges appear more efficient than ...
Chantal, Loirat +3 more
openaire +2 more sources
Skin Involvement in Atypical Hemolytic Uremic Syndrome
American Journal of Kidney Diseases, 2014Skin involvement in atypical hemolytic uremic syndrome (aHUS) is very uncommon and therefore often unrecognized as a specific symptom of aHUS. We describe 3 cases of patients with aHUS who developed skin lesions that completely recovered when disease-specific treatment was established.
ARDISSINO, GIAN LUIGI +6 more
openaire +3 more sources
An Atypical Case of Atypical Hemolytic Uremic Syndrome
Journal of Pediatric Hematology/Oncology, 2019We present the case of a 2-month-old infant presenting with pallor and laboratory results showing: hemoglobin 5.1 (10 to 1.5) g/dL, MCV 94.7 (75 to 105) fL, leukocytes 17.4 (7 to 15) ×103/μL, platelets 259 (150 to 450) ×103/μL, hyperbilirubinemia and renal dysfunction.
Tine, Francois +3 more
openaire +2 more sources
Refractory Atypical Hemolytic Uremic Syndrome
Blood, 2012Abstract Abstract 4635 Atypical hemolytic uremic syndrome is a rare but often lethal disease if not diagnosed and treated early. The mainstay of treatment has been plasma exchange, though eculizumab has recently been approved for treatment.
Ju-Hsien Chao +2 more
openaire +1 more source
Atypical hemolytic uraemic syndrome
Medicina Clínica (English Edition), 2015The hemolytic uremic syndrome (HUS) is a clinical entity characterized by thrombocytopenia, non-immune hemolytic anemia and renal impairment. Kidney pathology shows thrombotic microangiopathy (TMA) with endothelial cell injury leading to thrombotic occlusion of arterioles and capillaries.
Miquel, Blasco Pelicano +2 more
openaire +2 more sources